Enovis Corp (ENOV) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Enovis Corp (ENOV) stock forecast summary
On Oct. 13, 2026, ENOV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Enovis Corp is a small-cap company with a market capitalization of $1.10B. It ranks number 9 by market capitalization among the 24 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast. Its P/B Ratio of 0.74x is the lowest of the 19 peers that report one.
A per-ticker accuracy statistic for ENOV is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ENOV included.
Follow ENOV freeENOV price chart and AI forecast
How ENOV ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Enovis Corp (ENOV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | ENOV | Rank |
|---|---|---|
| Market Cap | $1.10B | 9/24 |
| P/B Ratio | 0.74x | 19/19 |
| EPS | $-20.13 | – |
| Book Value/Share | $25.61 | – |
| Revenue/Share | $39.82 | – |
| FCF/Share | $1.10 | – |
Profitability & Margins
| Metric | ENOV | Rank |
|---|---|---|
| ROE | -74.6% | 13/20 |
| ROA | -29.2% | 12/20 |
| ROIC | -32.9% | 13/21 |
| Gross Margin | 61.1% | 9/20 |
| Operating Margin | -45.1% | 13/21 |
| Net Margin | -48.0% | 14/18 |
| EBT Margin | -46.5% | 13/21 |
| Tax Rate | -2.9% | – |
Financial Health
| Metric | ENOV | Rank |
|---|---|---|
| Current Ratio | 1.98x | 17/24 |
| Quick Ratio | 1.00x | 19/21 |
| D/E Ratio | 1.55x | 6/23 |
| Financial Leverage | 2.55x | 6/23 |
| Interest Coverage | 2.2x | 6/21 |
| Working Capital | $603M | 6/22 |
Cash Flow
| Metric | ENOV | Rank |
|---|---|---|
| Operating Cash Flow | $270M | 6/22 |
| Free Cash Flow | $64M | 6/16 |
| Capital Spending | -$206M | 14/16 |
| OCF Growth YoY | 43.6% | 3/9 |
| FCF/Sales | 2.8% | 8/16 |
| CapEx/Sales | 9.0% | 2/16 |
Operational Efficiency
| Metric | ENOV | Rank |
|---|---|---|
| Asset Turnover | 0.61x | 13/18 |
| Receivables Turnover | 5.2x | 10/16 |
| Inventory Turnover | 1.5x | 15/21 |
| Fixed Assets Turnover | 4.3x | 11/18 |
| Days Sales Outstanding | 70 days | 7/16 |
| Days Inventory | 246 days | 7/21 |
| Payables Period | 79 days | 7/18 |
| Cash Conversion Cycle | 237 days | 3/15 |
Income Statement
| Metric | ENOV | Rank |
|---|---|---|
| Total Revenue | $2.30B | 4/18 |
| Operating Income | -$1.04B | 22/22 |
| Net Income | -$1.10B | 18/18 |
| R&D Expense | $124M | 4/19 |
| SG&A Expense | $1.08B | 5/19 |
| Cost of Goods Sold | $894M | 6/20 |
Dividend & Shareholder Information
| Metric | ENOV | Rank |
|---|---|---|
| Shares Outstanding | 58M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.21B | 32.3% of assets |
| Cash & Short-term Investments | $13M | 0.3% of assets |
| Accounts Receivable | $442M | 11.7% of assets |
| Inventory | $602M | 16.0% of assets |
| Total Liabilities | $2.29B | 60.7% of assets |
| Short-term Debt | $418M | 11.1% of assets |
ENOV quarterly financials and insider trading
Enovis Corp (ENOV) industry peers
Companies classified under the same SEC industry code as Enovis Corp (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ENOV Enovis Corp | ▶ | $1.10B |
| ISRG Intuitive Surgical Inc | ▼ | $149.10B |
| SNN Smith & Nephew Plc | ▼ | $24.45B |
| STE Steris Plc | ▼ | $21.23B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $17.56B |
| ALGN Align Technology Inc | ▶ | $10.20B |
| MSA Msa Safety Inc | ▼ | $7.01B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.74B |
| CDRE Cadre Holdings, Inc. | ▲ | $1.12B |
| AVR Anteris Technologies Global Corp. | ▼ | $629M |
| SMTI Sanara Medtech Inc. | ▼ | $323M |
| INGN Inogen Inc | ▶ | $168M |
| LAKE Lakeland Industries Inc | ▲ | $97M |
| NTRB Nutriband Inc. | ▲ | $79M |
| APT Alpha Pro Tech Ltd | ▲ | $59M |
| MYO Myomo, Inc. | ▲ | $51M |
| COCH Envoy Medical, Inc. | ▶ | $51M |
| MLSS Milestone Scientific Inc. | ▲ | $30M |
| LFWD Lifeward Ltd. | ▲ | $17M |
| UEEC United Health Products, Inc. | ▶ | $12M |
| RGNT Regentis Biomaterials Ltd. | ▶ | $8M |
| CLGN Collplant Biotechnologies Ltd | ▲ | $5M |
| FEED Envue Medical, Inc. | ▼ | $510K |
| RBOT Vicarious Surgical Inc. | ▶ | $320K |
| BBLG Bone Biologics Corp | ▲ | N/A |
| CUPR Cuprina Holdings (Cayman) Ltd | ▼ | N/A |
| LGMK Logicmark, Inc. | ▶ | N/A |
Where ENOV sits on the market map
Enovis Corp (ENOV) stock news
Loading...
Enovis Corp (ENOV) stock forecast FAQ
What is the Enovis Corp (ENOV) stock forecast?
On Oct. 13, 2026, ENOV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Enovis Corp stock predictions?
A per-ticker accuracy statistic for ENOV is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Enovis Corp forecasts updated?
Enovis Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Enovis Corp's industry peers?
27 issuers in our coverage, ENOV included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Smith & Nephew Plc (SNN), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.